Abstract:Background: Depressive symptoms are one of the main clinical features of the cerebral small-vessel disease (CSVD). However, the pathogenesis of depressive symptoms of CSVD has not been fully studied, and a lack of effective diagnostic methodseffective diagnostic methods exists. Recently, the emerging body of evidence regarding exosomes has rendered them potentially key players in the neuropsychiatric disease theragnostic. This study's aim was to investigate serum-exosome proteomic expression in CSVD patients with depressive symptoms and to screen and analyze potential biomarkers for clinical diagnosis. Methods: Serum samples were collected from 36 CSVD patients, including 18 cerebral small-vessel disease (CSVD+D) patients with depressive clinical manifestations and 18 cerebral small-vessel disease patients that did not present depression-related clinical manifestations (CSVD-D). This investigation employed tandem mass tag (TMT) combined with mass spectrometry for sample detection and quantitative analysis of proteins. The differential proteins with significant dysregulated expression levels in patient plasma exosomes were screened and analyzed through bioinformatics techniques. Results: This investigation focused on a global collection of 659 quantifiable proteins. Compared to the CSVD-D group, 7 up-regulated and 30 down-regulated proteins were identified in the CSVD+D group (P < 0.05). Gene ontology (GO) enrichment analyses revealed proteomic expression profile dysregulations within serum exosomes in patients with depression, such as desmosomes and keratins, rendering them as potential biomarkers. Kyoto encyclopedia of genes and genomes (KEGG) database investigations revealed the differentially expressed proteins to be highly aggregated within the estrogen signaling pathway. Conclusion: This investigation pioneered TMT proteomic evaluation of serum exosomes within CSVD patients suffering from depression and reveals the shifts in proteomic expression profiles by serum exosomes within such patients. This study identified several important molecular / signal pathway abnormalities related to depression. These results provide a possible means to further clarify the pathogenesis of depressive symptoms of cerebrovascular disease and its diagnosis and treatment in the future.

Glycosylation state of vWF in circulating extracellular vesicles serves as a novel biomarker for predicting depression.

Glycosylation state of vWF in circulating extracellular vesicles serves as a novel biomarker for predicting depression

Extracellular Vesicles in Mental Disorders: A State-of-art Review.

The roles of extracellular vesicles in major depressive disorder

Vitamin D-binding protein in plasma microglia-derived extracellular vesicles as a potential biomarker for major depressive disorder

In vivo evidence of increased vascular endothelial growth factor in patients with major depressive disorder

Investigating Neuroplasticity Changes Reflected by BDNF Levels in Astrocyte-Derived Extracellular Vesicles in Patients with Depression

Low VGF is Associated with Executive Dysfunction in Patients with Major Depressive Disorder

Potential biomarkers: differentially expressed proteins of the extrinsic coagulation pathway in plasma samples from patients with depression

Tandem Mass Tag (TMT) Quantitative Proteomic Analysis of Serum Exosomes in Cerebral Small-vessel Disease (CSVD) Patients With Depressive Symptoms

Abnormal Expression Profile of Plasma-Derived Exosomal Micrornas in Patients with Treatment-Resistant Depression

An Analysis of Plasma Reveals Proteins in the Acute Phase Response Pathway to Be Candidate Diagnostic Biomarkers for Depression

Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Epidermal Growth Factor in the Brain: A Promising Biomarker for Depression

Lower Plasma Levels of Selective VGF (Non-Acronymic) Peptides in Bipolar Disorder: Comparative Analysis Reveals Distinct Patterns across Mood Disorders and Healthy Controls

Elevated Level of Small Extracellular Vesicles in the Serum of Patients With Depression, Epilepsy and Epilepsy with Depression

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Serum proteomic biomarker investigation of vascular depression using data-independent acquisition: a pilot study

Reduced Serum VGF Levels Were Reversed by Antidepressant Treatment in Depressed Patients

Higher Serum VGF Protein Levels Discriminate Bipolar Depression from Major Depressive Disorder